Vol 2022, No 5 (2022)

Table of Contents

Research & Development

Amphista Enters Protein Degradation Collaborations with Bristol-Myers Squibb and Merck Abstract pdf html
Lucy Haggerty

Licensing

Jazz Licenses Sumitomo’s Narcolepsy Drug for US$50 M Upfront Abstract html pdf
Lucy Haggerty
Bristol Myers Squibb Licenses BridgeBio’s BBP-398 for Cancer Abstract pdf html
Lucy Haggerty

Mergers & Acquisitions

Pfizer Buys Biohaven for US$11.6 B Abstract pdf html
Lucy Haggerty


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.